Longaeva Partners’s Spyre Therapeutics SYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.33M Buy
+48,645
New +$4.68M 0.09% 193

Other funds holding SYRE

Longaeva Partners's SYRE Position: Q3 2026 in Review

Longaeva Partners opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 48,645 shares worth $4.33M. The stake represents 0.09% of the portfolio and ranks #193 among its holdings.

286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

  • Longaeva Partners held 48,645 shares of Spyre Therapeutics worth $4.33M as of Q3 2026.
  • Spyre Therapeutics was a new Longaeva Partners position in Q3 2026.
  • Spyre Therapeutics made up 0.09% of Longaeva Partners's portfolio in Q3 2026, its #193 holding.
  • 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Longaeva Partners's 13F filing for Q3 2026, filed 16 Nov 2026.